Results 251 to 260 of about 6,578,993 (340)

Therapeutic potential of natural products in cancer immunotherapy: Advances and challenges

British Journal of Pharmacology, EarlyView.
This review systematically outlines the mechanisms underlying tumour immunotherapy resistance and elucidates the role of natural products in enhancing therapeutic efficacy as immunomodulatory adjuvants. Abstract Immunotherapy has emerged as a clinically pivotal approach in cancer treatment, but its application remains limited to a small subset of ...
Rao Hu, Kaibin Dai, Zhensheng Lin, Mingfang Ye, Minfeng Chen, Xiaobo Li, Dongmei Zhang   +6 more
wiley   +1 more source

Restoring sensitivity to daratumumab with all-transretinoic acid in a patient with daratumumab-refractory multiple myeloma: A case report and review of the literature

Current Problems in Cancer: Case Reports
Noa Biran, David H. Vesole, Harsh Parmar, Pooja Phull, Susan Kumka, Kimberley Doucette, Joshua Zenreich, Bianca DeAgresta, Alexandra Della Pia, Lisa Biamonte, Martha Campanaro, Trina McClendon, Samanta BaboolallAracena, Palka Anand, Adolfo Aleman, Monique Pace, Genevieve Breeze, Kristin Ivanovski, Marie Layton, David S. Siegel   +19 more
doaj   +1 more source

Genomic mechanisms of resistance to venetoclax in multiple myeloma with t(11;14)(CCND1;IGH).

Blood
Kaddoura M, Wiedmeier-Nutor JE, Gupta VA, Jelinek T, Ziccheddu B, Shivaram S, Tang H, Owens RW, Sevcikova T, Fonseca R, Durante M, Diamond B, Zhao L, Zhu YX, Shi CX, Matulis SM, Mitsiades CS, Landgren O, Usmani S, Hajek R, Chesi M, Bergsagel PL, Braggio E, Boise LH, Fonseca R, Kumar S, Maura F, Baughn LB.   +27 more
europepmc   +1 more source

Targeting protein–protein interactions with reversible covalent modalities: Non‐cysteine chemistries

British Journal of Pharmacology, EarlyView.
Abstract Protein–protein interactions (PPIs) are central to diverse cellular functions, and represent a rapidly expanding class of therapeutic targets. Advancements in covalent drug design have enabled small‐molecule drugs to overcome challenges associated with engaging these targets, such as limited durations of action and difficult‐to‐drug (expansive,
Ruchira Basu, Steven Fletcher
wiley   +1 more source

Enhancing antitumour response to proteasome inhibitors with inhibitors of insulin‐degrading enzyme, a new molecular vulnerability in multiple myeloma

British Journal of Pharmacology, EarlyView.
Inhibitors of insulin‐degrading enzyme boost PI cytotoxicity through an increased sensitivity of proteasome to PI inhibitors, induction of ISR, DNA damage and Myc down‐regulation. They overcome PI resistance in vitro and induce tumour regression in vivo.
Laetitia Lesire, Rebecca Deprez‐Poulain, Damien Bosc, Florence Leroux, Valerie Landry, Sarah Ourabah, Morgane Tardy, Clara Maillard, Ronan Gealageas, Julie Dumont, Adrien Herledan, Sandrine Warenghem, Manon Cruette, Celine Lenglart, Alexandre Biela, Catherine Piveteau, Eva De Smedt, Catharina Muylaert, Wenguang Liang, Elvira Garcia De Paco, Elina Alaterre, Sara Ovejero, Nicolas Robert, Fabien Delahaye, Wei‐Jen Tang, Peter van Endert, Elke De Bruyne, Jérôme Moreaux, Benoit Deprez   +28 more
wiley   +1 more source

Bioenergetic diversity and nutrient auxotrophy shape the metabolic landscape of multiple myeloma. [PDF]

Blood Adv
Chong PSY, Lim JSL, Tan TZ, Kong LR, de Mel S, Leow ACY, Yap EGS, Chng WJ.   +7 more
europepmc   +1 more source

Bispecific Ligand‐Based EphB4 CAR‐T Cells Generated Using Ephrin‐B2 Show Potent Antitumor Activity Against Lung Adenocarcinoma

Cancer Science, EarlyView.
EphB4 and EphA2 positivity in lung adenocarcinoma samples was high. Ligand‐based EphB4 CAR‐T cells exhibit bispecificity, targeting both EphB4 and EphA2. EphB4 CAR‐T cells exert significant antitumor effects against lung adenocarcinoma. ABSTRACT Chimeric antigen receptor (CAR)‐T cells generated using ephrin‐B2, the natural ligand for ephrin type‐B ...
Hirotaka Kumeda, Koichi Hirabayashi, Shuji Mishima, Kotaro Morita, Yu Furui, Marina Fujioka, Tomoyuki Nakajima, Miyuki Tanaka, Yoshinori Sato, Takeshi Uehara, Shigeki Yagyu, Kimihiro Shimizu, Yozo Nakazawa   +12 more
wiley   +1 more source

Obesity Accelerates Multiple Myeloma Progression in Certain Mouse Models and in Humans. [PDF]

Cancer Prev Res (Phila)
Fairfield H, Marinac CR, Hamidi H, Knox K, Nestor B, Marques-Mourlet C, Diaz G, Wong CV, Mishra AK, Schimelman A, Qiang YW, Karam M, Farrell M, Jachimowicz E, Stohn JP, Birmann BM, Cornelius P, Reagan MR.   +17 more
europepmc   +1 more source

Decreased Expression of FAT4 Promotes Multiple Myeloma Proliferation and Migration by Targeting the Hippo/YAP Pathway

Cancer Science, EarlyView.
This study provides the first comprehensive characterization of the functional impact, and mechanistic role of FAT4 in MM. Our findings highlight the tumor‐suppressive role of FAT4 in MM and uncover a novel mechanism by which FAT4 regulates the Hippo/YAP pathway.
Lina Zhang, Na Shen, Xin Cheng, Qinglin Shi, Lijuan Chen, Xuxing Shen   +5 more
wiley   +1 more source

A case of solitary bone plasmacytoma to multiple myeloma: a case report. [PDF]

Front Med (Lausanne)
Fang Z, Tian Z, Tang J, Lei B, He Z, Zhu C, Luo H, Fu N, Shen Y.   +8 more
europepmc   +1 more source